Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NAD Recommends InterHealth Modify Advertising for Zychrome - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

NAD Recommends InterHealth Modify Advertising for Zychrome

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

The National Advertising Division (NAD), an investigative unit of the advertising industry’s system of self-regulation that is administered by the Council of Better Business Bureaus, has recommended that InterHealth Nutraceuticals, Benecia, CA, discontinue certain claims for the company’s Zychrome chromium, promoted for the management of insulin levels.

Print and Internet claims made by InterHealth for its Zychrome chromium compound, also known as chromium dinicocysteinate (CDNC), were challenged by Nutrition 21, LLC, the manufacturer of a competing product, Chromax, a chromium picolinate product.

Key challenged claims included: “The only form of chromium clinically shown to be twice as effective as chromium picolinate for managing insulin levels; 2x more effective than chromium picolinate in improving insulin function; 2x more effective than chromium picolinate in managing insulin resistance; and clinically studied to be twice as effective as chromium picolinate for maintaining healthy insulin function,” among others.

In this case, the advertiser’s primary source of claims support was a single preliminary study, in which differences between the Chromax and Zychrome groups did not reach statistical significance for any variable measured. The advertiser, NAD noted, did not rely on head-to-head test results to support its comparative efficacy claims.

Following its review of the evidence in the record, NAD recommended that the advertiser discontinue all claims at issue, with one exception: CDNC is a new form of chromium compound, a fact that the advertiser is free to promote.

InterHealth Nutraceuticals, in its advertiser’s statement, said the company “will modify advertising for Zychrome in accordance with the NAD’s recommendations.”

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics